# Efficacy of Targeted Medical Therapy in Angina and Nonobstructive Coronary Arteries

Study · id `cardio:ct-nct06424834` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06424834](<https://clinicaltrials.gov/study/NCT06424834>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT06424834

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 150 participants.

## Technical summary

Registry record NCT06424834. Randomized; quadruple masking; primary purpose treatment. Start 2024-10-10 (actual); primary completion 2026-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 150 participants (planned count; ClinicalTrials.gov record NCT06424834, source copy `cardio:ctgov-nct06424834-2024-11-27`, retrieved 2026-11-18)
- Started: 2024-10-10 (actual) (ClinicalTrials.gov record NCT06424834, source copy `cardio:ctgov-nct06424834-2024-11-27`, retrieved 2026-11-18)
- Primary completion: 2026-12 (anticipated) (ClinicalTrials.gov record NCT06424834, source copy `cardio:ctgov-nct06424834-2024-11-27`, retrieved 2026-11-18)
- Completion: 2026-12 (anticipated) (ClinicalTrials.gov record NCT06424834, source copy `cardio:ctgov-nct06424834-2024-11-27`, retrieved 2026-11-18)
- Countries: United States (ClinicalTrials.gov record NCT06424834, source copy `cardio:ctgov-nct06424834-2024-11-27`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06424834-2024-11-27`, retrieved 2026-11-18)

## The registry's words

- Brief title: Efficacy of Targeted Medical Therapy in Angina and Nonobstructive Coronary Arteries
- Acronym: MVP-ANOCA
- Condition: Angina Pectoris
- Condition: Microvascular Angina
- Condition: Vasospastic Angina
- Condition: Myocardial Bridge of Coronary Artery
- Intervention (Drug): Amlodipine
- Intervention (Drug): Nebivolol
- Intervention (Drug): Placebo
- Lead sponsor: Stanford University
- Lead sponsor class: OTHER
- Collaborator: American Heart Association
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Angina pectoris (`cardio:angina-pectoris`)
- Registry condition terms include this condition: Microvascular and vasospastic angina (`cardio:microvascular-and-vasospastic-angina`)
- Registry intervention name matches this record: Amlodipine (`cardio:amlodipine`)
- Registry intervention name matches this record: Nebivolol (`cardio:nebivolol`)
- Registry lists this organization as the lead sponsor: Stanford University (`cardio:org-stanford-university`)
- Registry lists this organization as a collaborator: American Heart Association (`core:aha`)

## Provenance

Content hash: 318ffceb3ce92d2cff893239218dab7cc4ba9045e6ba781030ea7e0cf5233d80
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
